Takes from Sitryx Webinar - Novel Oral Mechanism for Atopic Dermatitis with Key Readout in 4Q26

Research evidence excerpt

Takes from Sitryx Webinar - Novel Oral Mechanism for Atopic Dermatitis with Key Readout in 4Q26

Biotechnology

EQUITY RESEARCH Industry Report

June 7, 2026

Takes from Sitryx Webinar - Novel Oral Mechanism for

Prices are as of 06/01/26. Atopic Dermatitis with Key Readout in 4Q26 Research Analysts:

Prakhar Agrawal As part of our private company webinar series, we hosted Sitryx CEO Iain 212-610-3614

Prakhar.Agrawal@cantor.com Kilty and CFO Adam Mostafa to discuss the company’s immunometabolism

platform and take a deeper look at its lead asset, SYX-5219, an oral PKM2

modulator currently in a Phase 1b trial in atopic dermatitis (AD), with a

readout expected in 4Q26.

In healthy volunteers, SYX-5219 has already demonstrated good TARC

(key PD marker in AD) reduction, comparable to IL-4/IL-13 drugs and

Kymera’s STAT6 degrader, giving management confidence in the success

of the upcoming Phase 1b AD trial.

PKM2 could also work in several other indications (e.g., asthma), but we

thought the link between PKM2 biology and obesity-related inflammation

was particularly interesting. Sitryx plans to test this in a basket trial focused

on inflammatory skin diseases.

Email us if you would like a replay of the webinar!

Company Background:

●Sitryx is a clinical-stage company focused on immunometabolism.

Management provided a great overview of why targeting certain

metabolic pathways that fuel pro-inflammatory responses could make

sense across different autoimmune indications.

○A targeted approach to metabolism in inflammatory diseases

is a new concept, but there is precedent with broader

approaches to cell metabolism, such as methotrexate.

●Lead pipeline drug SYX-5219, a first-in-class PKM2 modulator, was the

focus of our webinar. Additional pipeline programs include: